



Daxor Corporation

Reports strong 2H 2021 revenue growth. Large market potential and increasing commercialization for its BVA-100 should drive stock. Raising our P/T to \$23.

2H 2021 report: Daxor recently (on March 1) reported its 2H 2021 (ending December) results. Net income was \$6.3 million or EPS of \$1.17 NAV (net asset value) per share was \$5.24, up from \$3.59 in 1H 2021. There was no consensus estimates or guidance.

Investment reporting: Daxor is registered as a diversified, closed-end management investment company. It does not report quarterly results like typical reporting companies, but report results semi-annually as an investment company. About half of its assets are investments (typically shares in publicly traded companies), and the other half is its investment in its operating division.

Focus on operating division: Daxor's operating division consist of its innovative biomedical diagnostics company that is the global leader in blood volume technology. Its main product is the BVA-100, a blood volume analyzer that is the first diagnostic blood test cleared by the FDA to provide blood volume status and composition in order to enhance hospital patient care in a broad range of surgical and medical conditions. Because Daxor reports results as an investment company, it does not provide specific results for its operating division.

Strong growth: The company had strong 71% (y-o-y) 2021 revenue growth in its blood volume business with growth across leading medical centers in the U.S.

No guidance: Management did not provide forward guidance. Due to its unique financial reporting, we do not provide forward financial estimates.

Key progress in 2022: The company accomplished several key milestones in 2H 2021 and is on track for more in 2022. These include significant progress in its next-generation BVA technology, funded by multiple contracts awarded by the U.S. Department of Defense. Daxor's next-generation technology is moving ahead with new analyzers projected for completion in the next 12 months.

BVA-100 market potential: BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions including heart failure and critical care by better informing treatment strategies, resulting in significantly better patient outcomes.

More clinical trials data soon: The company has a number of multi-center studies of BVA use. Some results are anticipated to be announced in 2022.

Commercialization ramp can be catalyst: We expect increased commercialization of its BVA-100 in 2022 (building on the strong momentum in 2021), along with to develop additional and improved technologies. We believe achieving key commercialization and development milestones and ramp up in revenues will likely be catalysts for the stock. Management anticipates there will be a sales force (internal and external) of over 50 soon.

Positive high risks versus high rewards: Overall, concerns outweighed by growth prospects and valuation. Daxor's diagnostic devices still have long commercialization challenges ahead, but we believe the ~billion dollars market potential presents high rewards for the risks. Because its operating division results are not disclosed, we believe the valuation for this business is misunderstood and significantly undervalued.

Raising P/T: We are maintaining our BUY rating, but raising our 12-month price target to \$23 from \$22 which is based on an NPV analysis. This represents significant upside from the current share price. We believe this valuation appropriately balances out the company's high risks with the company's high growth prospects and large upside opportunities.

Company Description

Based in Oak Ridge, TN, Daxor is a closed-end investment company, but has a large operating division that is an innovative biomedical diagnostic company that is the global leader in blood volume technology.

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$8.58 – 15.46
Shares Outstanding (million):	4.0
Market cap (\$million):	\$44
EV (\$million):	\$44
Debt (\$million):	\$0
Cash (\$million):	\$0
Avg. Daily Trading Vol. (\$million):	~\$0.1
Float (million shares):	1
Short Interest (million shares):	~0
Dividend, annual (yield):	\$0 (NA%)

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 16.

COMPANY UPDATE

Rating: BUY

Ticker: DXR

Price: \$11.08

Target: \$23.00
(from \$22)

Exhibit 1: Daxor Corporation

Corporate Profile

Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.

Management Team


Michael Feldschuh – CEO & President
Jonathan Feldschuh – Chief Scientific Officer
Kathryn A. Kornafel – VP Marketing & Commercial Development
Robert Michel – Chief Financial Officer
Jean Oertel – Sr. VP Commercialization & Customer Experience
Soren Thompson – VP Business Development

Board of Directors

Michael Feldschuh – Director
Henry D. Cremisi, MD, FACP – Director
Jonathan Feldschuh – Chief Scientific Officer
Edward S. Feuer – Director
Joy Goudie, Esq. – Director
James A. Lombard – Director
Caleb DesRosiers – Director

Source: Company reports

Exhibit 2: Company Timeline



Source: Company reports

Exhibit 3: Daxor Financial Highlights


	Year Ended December 31, 2021	Year Ended December 31, 2020
Net Asset Value Per Share, Beginning of Year	<u>\$ 3.89</u>	<u>\$ 3.41</u>
Income (loss) from operations:		
Net investment (loss) income	(0.20)	(0.08)
Net realized and unrealized gain (loss) from investments, options and securities borrowed	0.21	(0.32)
Net realized and unrealized gain from operating division	1.16	0.11
Other	(0.0)	0.01
Total gain from Operations	<u>1.17</u>	<u>(0.28)</u>
Capital share transactions:		
Proceeds from sale of treasury stock and exercise of stock options	0.00	0.70
Increase in net assets from stock based compensation	0.18	0.06
Increase in Net Asset Value Per Share	<u>1.35</u>	<u>0.48</u>
Net Asset Value Per Share, End of Year	<u>\$ 5.24</u>	<u>\$ 3.89</u>
Market Price Per Share of Common Stock, Beginning of Year	\$ 12.50	\$ 9.40
Market Price Per Share of Common Stock, End of Year	<u>\$ 11.29</u>	<u>\$ 12.50</u>
Change in Price Per Share of Common Stock	<u>\$ (1.21)</u>	<u>\$ 3.10</u>
Total Investment Return	<u>(9.68)%</u>	<u>32.98%</u>
Weighted Average Shares Outstanding	<u>4,036,660</u>	<u>3,935,902</u>

Source: Company reports.

Exhibit 4: Why is Blood Volume Analysis Important?

The Smallest Volume is the Most Vital for Survival


It is crucial to differentiate between interstitial overload and intravascular overload. The BVA-100 blood test directly quantifies the intravascular blood, plasma and red cell giving you actionable information you need to achieve optimal fluid management.



Interstitial: 11-13 L | Intracellular: 27-30 L | Intravascular: 3.0-3.5 L

Managing Volume Derangement is a Challenge with High Stakes

The Goal: Get the Patient to Their Optimal Blood Volume



Source: Company reports

Exhibit 5: Daxor's BVA-100

What is the BVA-100?

The BVA-100 is an FDA-cleared diagnostic test approved to:

- Measure intravascular total blood volume, red blood cell volume and plasma volume
- Calculate patient-specific ideal volumes based on height, weight and gender
- Quantify the percent deviation from the predicted ideal normal value in milliliters and as a percentage expressing whether the patient has normal, expanded or depleted volumes
- Report the albumin transudation rate as an indicator of capillary permeability

Dozens of published peer-reviewed studies across many medical conditions have proven the BVA-100's unique safety, accuracy, efficacy, and value. Accurate quantification of total blood volume, plasma volume, and red blood cell volume analysis informs physicians leading to better treatment strategies and better patient outcomes.

Source: Company reports.

Exhibit 6: BVA-100 Blood Test

DAXOR BVA-100 BLOOD TEST

Leader in the New Measure of Care

Over 50,000+ tests performed to evaluate blood volume and used daily in major centers across the U.S. Dozens of peer-reviewed studies have established the value of Blood Volume Analysis (BVA), confirming that accurate blood volume measurement leads to better outcomes.

Achieve Better Outcomes

Significantly Reduce Heart Failure Mortality & Readmissions*

Propensity matched-control trial in community hospital | n = 245, Mixed HFpEF/HFrEF



Blood Volume Measurements Improved ICU Survival[†]

Prospective randomized control trial in surgical ICU | n = 100, 70% Septic Shock/Sepsis/40% ARDS



Excellent Value in Healthcare

Blood Volume-Guided Treatment Extremely Cost-Effective[‡]

Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF



Approved for Reimbursement




Source: Company reports.

Exhibit 7: How BVA-100 Works

Basic Principle of Blood Volume Analysis

The BVA-100 Blood Volume Analyzer quantifies circulating blood volume utilizing the gold standard methodology the indicator tracer dilution technique. A dose of Volumex® Albumin I-131 tracer is injected intravascularly. Once the tracer has fully circulated in the bloodstream, a series of small blood samples are drawn. The BVA-100 automatically calculates patient blood volume by comparing the concentration of undiluted tracer prior to injection to the tracer concentration diluted in the patient blood samples.



The human figures represent sequential calculated blood volumes at the recommended intervals for drawing blood samples after tracer injection.

As the Volumex® tracer transudates from the intravascular to the extravascular space (depicted as the pink dots moving outside the red vein), the quantity of tracer decreases intravascularly implying a higher dilution factor and therefore higher blood volume.

The red line represents is the regression calculation of the analyzed draws to time zero or time of injection, which indicates the level of true total intravascular blood volume.


The red line is also a measure of albumin transudation, a measure of capillary permeability.

Source: Company reports.

Exhibit 8: Using BVA-100

98% Accurate Measurement of Intravascular Blood Volume Utilizing the 'Gold Standard' Methodology

The BVA-100 Blood Volume Analyzer quantifies blood volume using the indicator tracer dilution technique. The test is administered at the bedside, blood samples are drawn and sent to the laboratory for processing.




Preliminary data available within 30 minutes to help guide decisions in emergency situations.

Source: Company reports.


Exhibit 9: BVA-100 Market Opportunities

Providing a Solution for the Most Common and Costly Conditions

Blood volume derangements are common in a broad range of medical and surgical conditions including heart failure, critical care, sepsis, syncope, surgical blood loss, and ARDS.




Where Daxor BVA-100 Blood Test Makes an Impact



Source: Company reports.

Exhibit 10: Daxor Corporation Stock Price (5-years)



Source: <https://bigcharts.marketwatch.com/>

FINANCIAL MODEL

Daxor Corporation

Income Statement (\$ millions)	Jun-19	Dec-19	2019	Jun-20	Dec-20	2020	Jun-21	Dec-21	2021
Fiscal Year End: December 31	1HA	2HA	FY-A	1HA	2HA	FY-A	1HA	2HA	FY-A
Dividend income	0.193	0.182	0.375	0.118	0.145	0.263	0.121	0.146	0.267
Other income	0.000	0.005	0.005	0.001	0.000	0.002	0.005	0.006	0.011
Investment Income	0.193	0.187	0.380	0.119	0.145	0.264	0.126	0.152	0.278
Investment administrative char	0.140	0.206	0.345	0.202	0.353	0.554	0.402	0.551	0.952
Dividend expense			0.000	0.084	0.020	0.104	0.010	0.010	0.020
Professional fees	0.021	0.018	0.039	0.021	0.018	0.039	0.018	0.021	0.039
Transfer fees	0.013	0.009	0.022	0.009	0.019	0.028	0.012	0.017	0.029
Interest and other fees	0.075	0.068	0.143	0.008	0.001	0.008	0.005	0.015	0.020
Restructuring, taxes, and other		(0.025)	(0.025)		0.009	0.009	0.003	0.030	0.032
Total operating expenses	0.249	0.275	0.524	0.323	0.420	0.743	0.449	0.644	1.093
Net investment income (loss)	(0.056)	(0.088)	(0.144)	(0.204)	(0.275)	(0.478)	(0.323)	(0.492)	(0.815)
Net Realized (loss) on Investm	0.651	3.037	3.688	(0.305)	(0.056)	(0.361)	0.042	0.030	0.072
Net Change In Unrealized (Dep	0.938	(2.401)	(1.463)	(1.905)	0.324	(1.582)	0.279	0.477	0.756
Net Realized (loss) on Operati	(1.091)	(1.486)	(2.577)	(1.134)	1.825	0.691	(1.547)	6.282	4.735
Income Tax Expense	(0.006)	0.006	0.000		0.025	0.025			0.000
Net income (loss)	0.436	(0.932)	(0.496)	(3.548)	1.843	(1.705)	(1.549)	6.297	4.748

Source: Company reports and Ascendant Capital Markets estimates.

Daxor Corporation

Balance Sheet (\$ millions) Fiscal Year End: December 31	Jun-19 1HA	Dec-19 2HA	Jun-20 1HA	Dec-20 2HA	Jun-21 1HA	Dec-21 2HA
Assets						
Investments in securities	11.960	8.570	6.589	6.872	7.159	7.717
<u>Investments in Operating Division</u>	<u>5.650</u>	<u>5.400</u>	<u>5.400</u>	<u>8.800</u>	<u>8.800</u>	<u>16.500</u>
Total investments at fair value	17.610	13.970	11.989	15.672	15.959	24.217
Cash						
Receivables from broker	0.038	0.033	2.820	0.647	0.629	0.711
Prepaid and other expenses	0.354	0.198	0.198	0.234	0.065	0.054
<u>Other</u>						
Total assets	18.002	14.201	15.007	16.553	16.653	24.982
Liabilities and net assets						
Margin loans payable	4.397	1.343	0.905	0.171	1.516	3.023
Options	0.001	0.014	0.122			0.003
Securities sold short			2.822	0.627	0.644	0.716
Accounts payable		0.079	0.004	0.080		0.087
Other						
<u>Short and long term debt</u>						
Total liabilities	4.398	1.435	3.852	0.878	2.160	3.829
Common stock						
Additional paid-in capital	10.967	11.061	11.224	11.438	11.805	12.167
Retained earnings	17.497	16.565	13.017	14.860	13.311	19.608
Treasury stock	(14.860)	(14.860)	(13.086)	(10.623)	(10.623)	(10.623)
<u>Other</u>						
Net Assets	13.604	12.766	11.156	15.675	14.493	21.153
Total net assets and liabilities	18.002	14.201	15.007	16.553	16.653	24.982
Net Asset Value Per Share	\$3.63	\$3.41	\$2.87	\$3.89	\$3.59	\$5.24

Source: Company reports and Ascendant Capital Markets estimates

Daxor Corporation

Changes in Net Assets (\$ millions)	Jun-19	Dec-19	2019	Jun-20	Dec-20	2020	Jun-21	Dec-21	2021
Fiscal Year End: December 31	1HA	2HA	FY-A	1HA	2HA	FY-A	1HA	2HA	FY-A
Change in Net Assets from Operations									
Net Investment Gain (Loss)	(0.056)	(0.088)	(0.144)	(0.204)	(0.275)	(0.478)	(0.323)	(0.492)	(0.815)
Net Realized (loss) on Investments	0.651	3.037	3.688	(0.305)	(0.056)	(0.361)	0.042	0.030	0.072
Change in unrealized depreciation	0.938	(2.401)	(1.463)	(1.905)	0.324	(1.582)	0.279	0.477	0.756
Net Realized loss in operating divisions	(1.091)	(1.486)	(2.577)	(1.134)	1.825	0.691	(1.547)	6.282	4.735
Other	(0.006)	0.006	0.000		0.025	0.025			0.000
Change in Net Assets from Operations	0.436	(0.932)	(0.496)	(3.548)	1.843	(1.705)	(1.549)	6.297	4.748
Capital Share Transactions									
Distribution			0.000			0.000			0.000
Net proceeds from shares sold				1.775	2.261	4.036			0.000
Increase in net assets from stock options	0.106	0.094	0.199	0.164	0.415	0.579	0.367	0.363	0.729
Change in Net Assets	0.542	(0.838)	(0.296)	(1.610)	4.520	2.910	(1.182)	6.659	5.478
Net Assets at Beginning of Period	13.062	13.604	13.062	12.766	11.156	12.766	15.675	14.493	15.675
Net Assets at End of Period	13.604	12.766	12.766	11.156	15.675	15.675	14.493	21.153	21.153
Capital Share Activity									
Shares Outstanding at End of Period	3.747	3.747		3.889	4.034		4.034	4.039	
Net Asset Value Per Share	\$ 3.63	\$ 3.41		\$ 2.87	\$ 3.89		\$ 3.59	\$ 5.24	

Source: Company reports and Ascendant Capital Markets estimates.

Daxor Corporation


Cash Flow Statement (\$ millions)	Jun-19	Dec-19	2019	Jun-20	Dec-20	2020	Jun-21	Dec-21	2021
Fiscal Year End: December 31	1HA	2HA	FY-A	1HA	2HA	FY-A	1HA	2HA	FY-A
Cash flows from operating activities									
Change in net assets from oper	0.436	(0.932)	(0.496)	(3.548)	1.843	(1.705)	(1.549)	6.297	4.748
Investments realized gains/losses	(0.651)	(3.037)	(3.688)	0.305	0.056	0.361	(0.042)	(0.030)	(0.072)
Investments unrealized depreciation	(0.938)	2.401	1.463	1.905	(3.724)	(1.818)	(0.279)	(0.477)	(0.756)
Investment in/advances to operating	1.091	(3.418)	(2.327)	1.134	(3.844)	(2.709)	(1.547)	(1.418)	(2.965)
Operating Division realized gains	(1.091)	3.668	2.577	(1.134)	3.844	2.709	1.547	(6.282)	(4.735)
Purchase of investments	-	-	-	(0.093)	(0.801)	(0.893)	-	-	-
Sale of investments	1.179	4.040	5.218	1.252	0.356	1.608	0.000	-	0.000
Proceeds from securities borrowed at fair value	-	-	-	15.970	0.598	16.568	0.087	0.037	0.124
Payments to cover securities borrowed at fair value	-	-	-	(14.431)	(2.485)	(16.915)	(0.036)	(0.013)	(0.049)
Stock comp	0.106	0.094	0.199	0.164	0.214	0.378	0.367	0.363	0.729
Accrued interest	(0.001)	0.005	0.004	0.013	(0.009)	0.003	0.008	(0.010)	(0.001)
Accounts payable and other	(0.073)	0.234	0.162	(0.075)	0.076	0.001	(0.080)	0.087	0.007
Other	-	-	-	-	(0.035)	(0.035)	0.190	0.021	0.211
Restricted cash	-	-	-	(2.800)	2.800	-	-	-	-
Net cash provided by operating activities	0.058	3.055	3.112	(1.337)	(1.111)	(2.448)	(1.334)	(1.425)	(2.759)
Cash flow from financing activities									
Proceeds from margin loan pay	1.337	1.179	2.516	2.450	0.575	3.025	1.674	2.034	3.708
Repayment of margin loan pay	(1.395)	(4.233)	(5.628)	(2.888)	(1.309)	(4.197)	(0.329)	(0.527)	(0.857)
Issuance of stock	-	-	-	1.762	2.274	4.036	-	-	-
Issuance of debt	-	-	-	-	-	-	-	-	-
Other	-	-	-	0.013	0.189	0.201	-	-	-
Dividends and distributions	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities	(0.058)	(3.055)	(3.112)	1.337	1.729	3.065	1.345	1.507	2.852
Effect of exchange rate on cash	-	-	-	-	-	-	-	-	-
Net Increase (Decrease) in Cash	0.000	-	0.000	(0.000)	0.618	0.618	0.011	0.082	0.093
Cash at beginning of period	-	0.000	-	0.000	0.000	0.000	0.618	0.629	0.618
Cash at end of period	0.000	0.000	0.000	0.000	0.618	0.618	0.629	0.711	0.711

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Daxor Corporation



Source: <https://bigcharts.marketwatch.com/>

	Report Date		Price
Report	Date	Rating	Target
1	5/15/2019	Buy	20.00
2	2/5/2020	Buy	20.00
3	3/2/2020	Buy	20.00
4	3/24/2021	Buy	21.00
5	9/6/2021	Buy	22.00

- Ascendant Capital Markets, LLC has not received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as

appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product/device candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize products, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech/medtech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

Strong Buy: We expect the stock to provide a total return of 30% or more within a 12-month period.

Buy: We expect the stock to provide a total return of between 10% and 30% within a 12-month period.

Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.

Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.

Speculative Buy: This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of January 15, 2022)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	40	98%	16	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	41	100%	16	39%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.